F. (1983), "Risk Judgments and Intention Measures after Reading about Prescription Drug Side Effects in the Format of a Patient Package Insert," The Journal of Consumer Affairs, 17 (2), 277-89.Keown, C. F.: Risk judgments and intention measures after reading about prescription drug side ...
Liability of Dispensing to an Inpatient an Estrogenic Drug without a Patient Package Insert 来自 Semantic Scholar 喜欢 0 阅读量: 8 作者: DB Brushwood DOI: 10.1093/ajhp/47.8.1804 年份: 1990 收藏 引用 批量引用 报错 分享 全部来源 求助全文 全文购买 academic.oup.com Semantic Scholar NCBI ...
A typical drug’s risks are communicated via the package insert and a patient package insert provided at the time of prescription dispensing. Depending on the physician and his office staff, risks may also be communicated at the time the prescription is written for the patient. Various issues ha...
1.2不良事件(AE) Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event (AE) can therefore be any unfavourable and unintended sign (including an ...
Patient package insert January 4, 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022529lbl.pdf. Accessed June 27, 2013. 13. Vivus Inc. Qsymia (phentermine and topiramate extended-release) capsules, for oral use. Patient package insert April 16, 2013. http://www.accessdata...
t 3. Mix the patient specimen by vigorously shaking the specimen transport tube for 5 seconds. o 4. Open the cartridge by lifting the cartridge lid. N 5. Unscrew the specimen transport tube cap (do not remove the cap). Remove the transfer pipette from the wrapper by opening - the end ...
patient must be considered. American Academy of Pediatrics Committee on Drugs has taken the view that the insert should be viewed as a useful guide to the physician; its recommendations should be judged on an equal footing with other publications and research reports. The package insert contains ...
8 However, the pharmacokinetics of abatacept and optimal dosing in this patient population are unknown. Because increased body weight is a risk factor for severe COVID-19 and is associated with increased abatacept clearance (CL),9 it is possible that the pharmacokinetics of abatacept may be ...
in combination with cyclosporine and corticosteroids has not been studied beyond one year; therefore after the first 12 months following transplantation, any adjustments to the immunosuppressive regimen should be considered on the basis of the clinical status of the patient [seeClinical Studies (14.3)]...
In the A+CnP arm, one patient had a grade 5 immune-related AE of abnormal hepatic function. Discussion IMpower131 met its coprimary end point of investigator-assessed PFS in the ITT population (median PFS: A+CnP, 6.3 mo versus CnP, 5.6 mo; stratified HR = 0.71; 95% CI: 0.60–0.85;...